Thoma Bravo has announced that it has acquired Bluesight Health, a drug diversion and inventory management company.
The deal, which was reportedly valued at $500 million, also includes the acquisition of Medacist, a provider of medication management software.
Bluesight’s vision is to transform the hospital pharmacy supply chain through software. Today, the company supports health systems with automated RFID-enabled kit and tray management through KitCheck™, controlled substance diversion management through ControlCheck™ and drug purchasing optimization through CostCheck™.
Additional resources from Thoma Bravo will help accelerate the realization of Bluesight’s vision and are expected to significantly benefit its customers.
Bluesight’s acquisition of Medacist combines two innovators in drug diversion analytics and medication management solutions that together will serve more than 2,000 hospitals across North America.
Bluesight’s advanced auditing capabilities and visibility across all hospital care areas complements Medacist’s streamlined reporting and visibility tools across the health system.
Healthcare organizations will have a single source of software solutions that provides insights into medication usage and diversion to allow for the most accurate predictions, targeted interventions and, ultimately, improved patient outcomes.
Kevin MacDonald, Co-Founder and CEO of Bluesight, will lead the combined organization.
Technological advancements, including artificial intelligence, are digitizing healthcare and driving demand for software innovations in medication management.
Health system pharmacies are looking for solutions that lower costs, increase efficiency, and improve compliance,” said Kevin MacDonald. Partnering with Thoma Bravo enables us to increase our investment in Medication Intelligence™ and serve our health system customers more completely across the drug lifecycle.
Joining forces with Medacist allows us to better support healthcare organizations in their effort to identify and prevent acts of drug diversion and creates a leading software platform providing seamless, secure and efficient medication surveillance and predictive analytics solutions.”
Bluesight and Medacist are both cloud-based companies that offer solutions to help healthcare organizations prevent and detect drug diversion.
Bluesight’s platform uses artificial intelligence to analyze data from electronic health records, pharmacy dispensing records, and other sources to identify potential cases of drug diversion.
Medacist’s software helps healthcare organizations track and manage controlled substances.
The acquisition of Bluesight and Medacist is Thoma Bravo’s latest move into the healthcare technology space. The firm has also invested in other healthcare technology companies, such as Change Healthcare, WellSky, and Kareo.
Thoma Bravo’s investment in Bluesight and Medacist is a sign of the growing importance of drug diversion prevention and detection in the healthcare industry.
Drug diversion is a serious problem that can have a significant impact on patient safety. By acquiring Bluesight and Medacist,
Thoma Bravo is positioned to help healthcare organizations address this important issue.
What does the acquisition mean for the healthcare industry?
The acquisition of Bluesight and Medacist by Thoma Bravo is a significant development for the healthcare industry.
The two companies offer a wide range of solutions that can help healthcare organizations prevent and detect drug diversion. This is a critical issue, as drug diversion can have a significant impact on patient safety.
The acquisition is also a sign of the growing importance of technology in the healthcare industry.
Bluesight and Medacist are both cloud-based companies that use artificial intelligence to analyze data.
This type of technology is becoming increasingly important in the healthcare industry, as it can help organizations to improve efficiency and accuracy.
What are the next steps for Bluesight and Medacist?
It is still too early to say what the next steps will be for Bluesight and Medacist.
However, it is likely that Thoma Bravo will invest in the two companies to help them grow and expand their offerings.
The firm has a track record of success in the healthcare technology space, so it is likely that it will be able to help Bluesight and Medacist to achieve their goals.
Source: Thoma Bravo
